Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA To Update Quality Metrics Guidance

Executive Summary

It's the only addition to the agency's 2016 agenda.

You may also be interested in...



Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?

Brand and generic industries are on opposite sides of spectrum on most issues; there is mutual opposition, however, to the use of a meaningless four-letter suffix in the proper name of a product.

Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?

Company's application development seems to be outpacing FDA's policy development in next step along the 351(k) pathway.

Biosimilar Labeling: FDA Says Leave Comparability Data Out

Data developed to show no clinically meaningful differences with the reference product could confuse prescribers, agency says in new draft guidance.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB001959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel